Middle East and Africa Prefilled Syringes Market Size, Share & COVID-19 Impact Analysis, By Material (Glass, and Plastic), By Product (Complete Syringe Set, and Components & Accessories), By Closing Segment (Staked Needle System, Luer Cone System, and Luer Lock Form System), By Design (Single-chamber, Double-chamber, and Multiple Chamber), By End User (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others), and Regional Forecast, 2021-2028

The Middle East and Africa prefilled syringes market size was USD 121.0 million in 2020. The market is projected to grow from USD 148.6 million in 2021 to USD 361.8 million in 2028 at a CAGR of 13.6% during the 2021-2028 period. The global impact of COVID-19 has been unprecedented and staggering, with pre-fillable syringe products witnessing a positive impact on demand across all regions amid the pandemic. Based on our analysis, the global market exhibited a higher growth of 17.5% in 2020 compared to the average year-on-year growth during 2017-2019. The rise in CAGR is attributable to this market’s demand and growth returning to pre-pandemic levels once the pandemic is over.

Prefilled syringes are injectable drug delivery systems intended to administer drugs via the parenteral route. These devices have become a gradually important option in the packaging and delivery of injectable drug products. This syringe is intended for two major purposes for the administration of a drug. The first is as primary packaging by assuring that there is no adverse effect on the drug's strength, identity, quality, potency, and purity over its shelf life. Second, this syringe is a delivery system intended to administer the appropriate amount of the drug to the patient reliably.

The increasing cased of chronic diseases such as cancer, arthritis, diabetes, and many others, is anticipated to boost the demand for these devices in the Middle East and Africa during the forecast period. According to the International Diabetes Federation, in 2020, around 60 million adult population lives with diabetes in MENA Region. The growing diagnosis and treatment rates of diabetes treatment globally are projected to drive the demand for insulin prefilled syringes in the Middle East and Africa.                                                                                              

Higher Demand for Prefilled Syringes in COVID-19 Vaccines to Propel Growth

The outbreak of COVID-19 has had a positive impact on the Middle East and Africa prefilled syringes market. Key players have reported growth in their revenues from the sales of these syringes during the COVID-19 pandemic. For instance, Ypsomed’s “delivery systems” segment that includes re-fillable syringes witnessed 23.6% growth between 2019- 2020. The same segment reported 17.5% growth during 2018-2019.

Additionally, various governments and prominent players are continuously planning to develop COVID-19 vaccines in these syringes. The purpose of this delivery system is to outline the minimum expectations for immunizers in the preparation, transportation, and administration COVID-19 vaccine.

• For instance, in May 2020, the U.S. government granted privately held ApiJect Systems Corp., a USD 138 million contract to produce pre-filled syringes for Covid-19 shots.

Thus, these devices could become more common in the next year or two. The increased demand is projected to continue during 2022 and return to pre-pandemic levels from 2023.

LATEST TRENDS

Request a Free sample to learn more about this report.

Product Innovations and Regional Expansions to Augment Market Growth

Growing demand for easy-to-use, convenient, cost-effective, and safe alternatives for conventional delivery systems has been witnessed in the region. Expansion of product portfolio by leading players to include advanced syringe designs, high-quality material, and launch of products to fulfill the growing demands of patient comfort and safety will create attractive opportunities for the market growth.

• For instance, in December 2020, BD (Becton, Dickinson and Company) announced the launch of the BD Neopak 2.25 mL pre-fillable glass syringe, specifically designed for biopharmaceutical manufacturers.

Furthermore, several companies are focusing solely on regional expansion. The huge unmet need for advanced and innovative product offerings and currently limited competition in developing markets offers significant potential for expanding business in these regions. Increasing focus on strengthening distribution channels in MEA regions will lead to increased revenue generation. This will further present lucrative market opportunities to market players to establish footprints in the market in developing regions.

DRIVING FACTORS

Growing Preference for Prefilled Syringes for Administration of Drugs to Boost Market Growth

Biologics have gained the attention of leading players as they target diseases with no or minimal treatment options, including several types of cancers, autoimmune diseases, and other non-communicable diseases. The growing cases of autoimmune diseases, cancer, and other non-contagious diseases is anticipated to bolster the biological drugs demand.

• As per the Middle East Arthritis Foundation, one in five people in the UAE suffers from some kind of arthritis, and rheumatoid arthritis is common among the adult population. Furthermore, Humira – a biologic from AbbVie Inc., witnesses a 3.5% growth in worldwide sales from USD 19,169 million in 2019 to USD 19,832 million in 2020.

The growing preference for prefilled syringes in the Middle East and Africa region, for the administration of biologics and biosimilar products has been observed among healthcare providers and product development scientists due to its advantages, such as improved convenience, dose accuracy, and self-administration. It also helps to save on the costs associated with overfilling.

RESTRAINING FACTORS

Limitations and Issues Related to Product Stability to Hamper Growth

These syringes are gaining popularity as preferred delivery systems for biological drugs. However, the complex designing, manufacturing, quality assurance, and stability testing methods of the syringes and drug components' stability are significant challenges faced by the manufacturers. The components of the syringe system can interact with the drug molecules resulting in product instability and adverse events. For example, silicon oil used to lubricate the inner surface of these syringes is an “essential evil” that cannot be avoided. Silicon oil ensures functionality and makes sure that the plunger can be pressed down more easily and smoothly.

But silicon is a source of extractable and leachable particles that react with the sensitive proteins leading to protein aggregation under certain conditions, which then presents the risk of immunogenicity and consecutively alters product stability, especially in the case of biologics and biosimilar drugs. Thus, product instability in the syringe can cause the container drugs incompatible with it, thereby decreasing demand during the coming years.

SEGMENTATION

By Material Analysis

To know how our report can help streamline your business, Speak to Analyst

Least Interaction Between Drug Compounds and Glass to Dominate Market

Based on type, the global market is segmented into glass and plastic.

The glass segment held the dominant share of the global market in 2020. Glass material is highly compatible with different drug filling machines and provides a streamlined regulatory approval of drugs integrated with glass syringes. Thus glass is the preferred choice of many pharmaceutical drug manufacturers for the storage of biological products, as the property of the glass material aids in the prevention of the interaction between drug compounds and water vapor & oxygen.

This is likely to support the growth of the glass material segment during the forecast period. However, the glass segment is anticipated to lose the market share slowly during the forecast period attributed to the concerns raised over glass quality, such as growing breakage rate and glass delamination and shifting the preference of manufacturers from glass to plastic material.

The plastic segment is anticipated to expand at a comparatively higher growth rate during the forecast period. This is attributed to the advantages offered by plastic material over the glass by introducing innovative polymers material offering high breakage resistance, enhanced quality, and transparency.

By Product Analysis

Technological Advancements Backed Higher Share of Complete Syringe Set Segment

On the basis of product, the market is segmented into complete syringe sets and components & accessories.

The complete syringe set segment held the dominating share of the market in 2020. The upsurge of technological advancements and accurate dosage delivery of biologics through prefilled syringes are likely to increase the demand for a complete syringe set during the forecast period. Furthermore, the higher CAGR is attributed to the rise in the preference for self-drug administration. Additionally, these devices are gaining high importance as an effective drug delivery system for biologics. These factors are anticipated to boost the complete syringe set segment during the forecast period.

The components & accessories segment is expected to grow at a noticeable CAGR during the forecast period. The growth of the segment is primarily due to the availability of multiple sizes & configurations of syringe components, and the rise in technological advancements in the form of compatibility, seal integrity, and maintaining the stability throughout the shelf life of drug products will contribute to propelling segment growth in the near future.

By Closing System Analysis

Growing Adoption of Staked Needle Accountable for Highest Share of Segment  

On the basis of the closing system, the market is segmented into staked needle system, a Luer cone system, and a Luer lock form system.

Among closing systems, the staked needle system segment held a dominant share of the market in 2020. The growing number of medical emergency cases in the MEA region and the increased usage of staked needle systems in prefilled syringes to speed up the treatment by reducing the time for selecting and attaching the needle during medical emergencies are the key factors expected to drive the demand for staked needle system syringes during the forecast period.

The Luer cone system segment is expected to grow at a noticeable CAGR during the forecast period. Rapidly growing adoption of the Luer cone system and the rising number of players offering advanced products are likely to fuel the growth of the Luer cone system segment during the forecast period.

• For instance, Gerresheimer AG offers ClearJect Luer cone syringes that are tungsten free which aids in the reduction of risks associated with drug & packaging material interaction.

By Design Analysis

Highest Share Attributed to Advantages Offered by Single-Chamber Prefilled Syringes

On the basis of product, the market is segmented into single-chamber, double-chamber, and multiple chambers.

The single-chamber segment held the largest share of the market in 2020. The high share is attributed to the advantages offered by single-chamber syringes to the pharmaceutical & biotech companies over vials. These syringes require less overfill resulting in minimum product waste, and aids in easing the drug's administration with its simple design model. Additionally, technological innovations and implementation in the filling procedures for single-chamber syringes and an upsurge in adopting a safety device assembled in these syringes to reduce the needle stick injuries among patients & healthcare providers & healthcare are projected to boost the demand for the single-chamber segment during the forecast period.

The double-chamber segment is anticipated to grow at a remarkable CAGR during the forecast period. The increasing penetration of lyophilized drugs among end-users is projected to uptick the demand for double-chamber syringes. Furthermore, the growing adoption of technologically advanced products and shifting preference from a single chamber to a double-chamber system is likely to boost the growth of the segment during the forecast period.

By End-User Analysis

Expansion of Pharmaceutical & Biotechnology Companies to Aid Growth of Segment     

Among end-users, the market segments include biotechnology & pharmaceutical companies operating in this industry, contract manufacturing & research organizations, and others. The pharmaceutical & biotechnology companies segment dominated the market in 2020 owing to the presence and expansion of several pharmaceutical & biotechnology companies, and prominent companies are involved in biologics vaccines, biosimilar, and other potent drugs. Additionally, a growing number of early-stage, well-funded biotech companies focusing on drug discovery and development are likely to boost the demand for prefilled syringes in the Middle East and Africa for the effective delivery of the drugs, further supporting the pharmaceutical & biotechnology companies’ segment's growth during the forecast period.

The contract research & manufacturing organizations segment is anticipated to register a higher CAGR during 2021-2028. The presence of advanced innovative technologies and services that offer syringe filling services are expected to boost contract research & manufacturing organizations' segment growth during the forecast period.

REGIONAL INSIGHTS

On the basis of country/ sub-region, the Middle East and Africa market is segmented into the key regions of GCC countries, South Africa, and Rest of Middle East & Africa.

The market value in GCC countries stood at USD 82.9 million in 2020. The primary reason responsible for the growth of the market in GCC countries is the rapid rise in the burden of chronic diseases and the rising demand for these syringes for insulin and other drug delivery. According to the International Diabetes Federation (IDF), 55 million adults (20-79) were living with diabetes in the Middle East and North Africa region in 2019. Furthermore, this figure is estimated to increase to 108 million by 2045. The rise in diabetic patients ultimately upsurges the demand for prefilled insulin syringes, contributing to the Middle East and Africa prefilled syringes market growth.

South Africa is estimated to be the prominent dominant region in terms of market share.  South Africa holds a significant share due to the growth of the country is attributed to the rapid rise in the burden of chronic diseases. For instance, according to the Joint United Nations Programme on HIV/AIDS, in South Africa, around 7.5 million people live with HIV.

The expansion of product offerings by many key players involved in prefilled syringes and focusing on geographic expansion through subsidiary or distributor in emerging countries such as Algeria, Bahrain, Egypt, Iran, Lebanon, etc., is anticipated to favor the growth of the market in the region during the forecast period.

KEY INDUSTRY PLAYERS

Becton, Dickinson and Company (BD), SCHOTT AG, and Gerresheimer AG Comprising of Noticeable Market Share

The competitive landscape of this market is consolidated, with players such as Becton, Dickinson and Company (BD), SCHOTT AG, Gerresheimer AG, West Pharmaceutical Services, Inc., Aptargroup, Inc., and Ypsomed AG accounting for a significant share in 2020. The company is reinforcing its strategic position in the market by emphasizing the development of innovative syringes.

The company offers a wide range of pre-fillable syringes to a large number of pharmaceutical manufacturing companies and strongly emphasis strengthening its distribution network through strategic collaboration with many research organizations to enlarge its customer base. For instance, BD Neopak 2.25 mL prefillable glass syringe developed with an advanced syringe technology system is used for the treatment of chronic diseases such as rheumatoid arthritis, psoriasis, and severe asthma. It reduces the interaction between the drug molecule and the primary packaging container.

LIST OF KEY COMPANIES PROFILED:

• BD (Becton, Dickinson and Company) (Franklin Lakes, New Jersey, U.S.)


• SCHOTT AG (Mainz, Germany)


• Gerresheimer AG (Düsseldorf, Germany)


• West Pharmaceutical Services, Inc. (Exton, U.S.)


• Aptargroup, Inc. (Crystal Lake, U.S.)


• Ypsomed AG (Burgdorf, Switzerland)


• Nipro Pharma Packaging International (Osaka, Japan)


• Terumo Medical Corporation (Tokyo, Japan)

KEY INDUSTRY DEVELOPMENTS:

• April 2021 - Nipro Pharma Packaging International expanded its product portfolio by announcing that the Nipro D2F pre-fillable syringes are compatible with Schreiner MediPharm Needle- Trap (safety system).


• October 2020 – SCHOTT AG and Credence MedSystems established a strategic collaboration to implement Credence Companion Technology with SCHOTT’s pre-fillable syriQ glass and SCHOTT TOPAC polymer syringe systems.

REPORT COVERAGE

An Infographic Representation of Middle East and Africa Prefilled Syringes Market

View Full Infographic

To get information on various segments, share your queries with us

The Middle East and Africa prefilled syringes market research report provides detailed market analysis and focuses on key aspects such as an overview of the advanced product, the prevalence of chronic disorders and key countries, and pricing analysis. Additionally, it includes an overview of reimbursement scenarios for products, key industry developments such as mergers, partnerships, & acquisitions, the impact of COVID-19 on the market, and brand analysis. Besides these, the report offers insights into key market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years. The report also covers regional analysis of different segments.

Report Scope & Segmentation